| |
Metal label
|
Specificity
|
Antibody clone
|
|---|
|
1
|
115In
|
Dead cells
|
n/a
|
|
2
|
140Ce
|
Beads
|
n/a
|
|
3
|
141Pr
|
CD25
|
M-A251
|
|
4
|
142Nd
|
CD19
|
HIB19
|
|
5
|
143Nd
|
IL-10
|
JES3-9D7
|
|
6
|
144Nd
|
IL-4
|
MP4-25D2
|
|
7
|
145Nd
|
CD4
|
RPA-T4
|
|
8
|
146Nd
|
CD8
|
RPA-T8
|
|
9
|
147Sm
|
CD20
|
2H7
|
|
10
|
148Nd
|
CD57
|
HCD57
|
|
11
|
149Sm
|
CTLA-4
|
14D3
|
|
12
|
150Nd
|
MIP-1β
|
D21–1351
|
|
13
|
151Eu
|
CD107a
|
H4A3
|
|
14
|
152Sm
|
TNFa
|
Mab11
|
|
15
|
153Eu
|
CD45RA
|
HI100
|
|
16
|
154Sm
|
CD3
|
UCHT1
|
|
17
|
155Gd
|
CD28
|
L293
|
|
18
|
156Gd
|
CD38
|
HB-7
|
|
19
|
157Gd
|
HLA-DR
|
G46–6
|
|
20
|
158Gd
|
CD33
|
WM53
|
|
21
|
159 Tb
|
GMCSF
|
BVD2-21C11
|
|
22
|
160Gd
|
CD14
|
M5E2
|
|
23
|
161Dy
|
IFNγ
|
4S.B3
|
|
24
|
162Dy
|
CD69
|
FN50
|
|
25
|
163Dy
|
TCRγδ
|
B1
|
|
26
|
164Dy
|
IL-17
|
N49–853
|
|
27
|
165Ho
|
CD127
|
A019D5
|
|
28
|
166Er
|
IL-2
|
MQ1-17 h12
|
|
29
|
167Er
|
CD27
|
L128
|
|
30
|
168Er
|
CD154 (CD40L)
|
24–31
|
|
31
|
169Tm
|
CCR7
|
150503
|
|
32
|
170Er
|
PD1
|
EH12.1
|
|
33
|
171Yb
|
Granzyme B
|
GB11
|
|
34
|
172Yb
|
PD-L2
|
24F.10C12
|
|
35
|
173Yb
|
Perforin
|
B-D48
|
|
36
|
174Yb
|
CD16
|
3G8
|
|
37
|
175Lu
|
PD-L1
|
29E.2A3
|
|
38
|
176Yb
|
CD56
|
NCAM16.2
|
|
39
|
191Ir
|
DNA1
|
n/a
|
|
40
|
193Ir
|
DNA2
|
n/a
|
- A 40-marker CyTOF panel for the phenotypic and functional analysis of immune cell subsets in melanoma patients treated with anti-CTLA-4 or anti-PD-1 therapy is shown. The element and isotope of the metal tag conjugated to each antibody and non-protein subject (italic) is indicated under the ‘Metal Label’ column. ‘Specificity’ indicates the target recognized by the metal-conjugated antibody or non-protein subject. 193Ir/195Ir DNA Intercalator and 115In Maleimide DOTA live/dead stain facilitate the identification of live intact singlets while calibration beads (140Ce) are important for data pre-processing. Antibody clones are listed when applicable
